Scottish biotech Mironid is in the preclinical stages of developing a treatment for autosomal dominant polycystic kidney disease, a genetic condition which for around half of patients can led to kidney failure by the time they reach 60 years of age. In Vivo spoke to chief medical officer Cass Kelleher about the company’s development strategy.

Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.

These are interesting times for Mironid, a Glasgow-based biotech developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease, a life-threatening hereditary condition.